Table 3.

Cost-effectiveness analysis results from the base case

Strategy	Discounted cost, $	Incremental cost, $	Discounted QALYs	Incremental QALYs	ICER, $/QALY
Comparator with ibrutinib as second-line therapy	336 418		3.09
Ibrutinib as initial therapy	791 670	455 252	5.49	2.40	189 326

Ibrutinib as first-line therapy was modeled to cost an additional $455 000 in health care costs and add an additional 2.40 QALYs compared with the modeled comparator, which assumes ibrutinib as second-line therapy. Costs are from a Medicare perspective and include additional health care costs.